TAK241220C15000
- 0.05
- 0.000.00%
Takeda Pharmaceutical Newsroom
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating
Express News | Hikma - Acquires Rights to a Portfolio of Takeda Brands for the Mena Region
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Takeda Pharmaceutical: Revised Extraordinary Report
Express News | Takeda Pharmaceutical's CD38 monoclonal antibody has been approved for clinical use again in China.
Takeda Pharmaceutical (TAK.US) CD38 monoclonal antibody has been approved for clinical use again in China.
Takeda Pharmaceutical's CD38 monoclonal antibody has been approved for clinical use in China again.
Regarding the launch of the strategic partnership "Project Soten" between Takeda Pharmaceutical and Tohoku Universities to accelerate the research and development of Innovative Drugs.
On December 17, 2024, Takeda Pharmaceuticals Sp Adr and Tohoku University announced the launch of a strategic alliance "Project Sōten" to accelerate research and development of Innovative Drugs - Building an advanced clinical trial acceleration model aimed at improving medical access for regional patients and strengthening domestic drug development capabilities - Accelerating the establishment of a medical network and healthcare data infrastructure centered on Tohoku University Hospital, promoting research and development of new drugs and treatments through integrated analysis, and contributing to the world from Tohoku.
Takeda Pharmaceutical Unveils $10 Billion-$20 Billion Late-Stage Pipeline
Express News | EMA: Benefit of Alofisel Used in Crohn’s Disease No Longer Demonstrated
Express News | EMA: Alofisel Withdrawn From the EU Market
6-K: Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
HUTCHMED (China) to Receive $10 Million Milestone Payment From Takeda After First European Reimbursement for Fruzaqla
Takeda Plans To Host An Investor R&D Day; Expects Six Late-Stage Programs With Peak Revenue Potential Of $10B - $20B To Deliver Sustainable Growth
List of Switching Stocks (Part 1) [Parabolic Signal Switching Stocks List]
○ List of stocks for Buy conversion in the market Code Stock Name Closing Price SAR Main Board <1605> INPEX 1982 1944 <1662> Petroleum Resources 1096 1056 <1938> Nihon Reitech 1127 1082 <1939> Shikoku Electric Power 1468 1427 <2127> Japan M&A 6496 616 <2150> CareNet 5915 71 <2335> CubeSys 1066 1037 <26
ADR Japan stock ranking~ General buying dominance such as Toyota Industries, Chicago at 39,335 yen, 305 yen higher than Osaka~
Japanese stocks of American Depositary Receipts (ADRs), when compared to the Tokyo Stock Exchange (converted at 1 dollar to 150.01 yen), saw increases for Toyota Industries <6201>, KDDI Corporation <9433>, Mitsubishi Corporation <8058>, Honda Motor Co., Ltd. <7267>, Tokyo Electron <8035>, Tokio Marine Holdings <8766>, Mizuho Financial Group <8411>, etc., with overall buying preference. The settlement price of Chicago Nikkei 225 futures was 305 yen higher than the Osaka intraday price, at 39,335 yen. The U.S. stock market is mixed. The Dow Jones Industrial Average is down 123.19 dollars at 44,6.
Express News | Takeda Pharmaceutical: selling 49% of the shares in the joint venture with Teva Pharmaceutical Industries, receiving 55 billion yen.
Takeda Pharmaceutical: To Receive Y55B From Sale of 49% Stake in JV With Teva Pharmaceutical Industries
Express News | Teva Pharmaceutical Industries of Israel will sell its joint venture business in Japan with Takeda Pharmaceutical to JKI, with the transaction expected to be completed by April 2025.
Regarding the transfer of the shareholding of Takeda Teva Pharma Co., Ltd. owned by our company.
Regarding the transfer of shareholding in Takeda Teva Pharma Co., Ltd., on December 5, 2024, it is announced that all of the 49% shareholding held by the company in its affiliated company, Takeda Teva Pharma Co., Ltd. (hereinafter referred to as "Takeda Teva Pharma"), will be transferred to Teva Pharmaceutical Industries Limited (hereinafter referred to as "Teva") and managed by a fund operated by J Will Partners, which will manage all of Takeda Teva Pharma's issued shares.
Takeda Pharmaceutical (TAK.US) collaborates with keros therapeutics to develop innovative treatments for blood diseases.
Takeda Pharmaceutical (TAK.US) is collaborating with keros therapeutics to develop innovative therapies for blood diseases.